Redifferentiation Therapy Using Alpha Lipoic Acid in Thyroid Cancer (RALT)

Asan Medical Center

Status and phase

Withdrawn

Phase 2

Conditions

Thyroid

Cancer

Treatments

Drug: alpha-lipoic acids

Study type

Interventional

Funder types

Other

Identifiers

NCT01396733

AMC_THY_001

Details and patient eligibility

About

Radioiodine (I-131) therapy is of proven efficacy for treatment of differentiated thyroid carcinoma (DTC). However, loss of differentiation in recurrent or metastatic DTC which decrease I-131 uptake may decrease the efficacy of I-131 therapy. Therefore, strategies to improve I-131 uptake are mandatory. This study is an open label clinical study to evaluate the effectiveness of alpha-lipoic acid (ALA) for improving I-131 uptake in recurrent or metastatic of DTC with defective I-131 uptake.

Sex

All

Ages

20 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

aged 20 to 75 years
under birth control, if fertile women
Groups
- who received radioactive iodine treatment for recurrent and metastatic thyroid cancer, and did not showed any uptake at post-therapeutic whole body scan
- who planned to receive empirical radioactive treatment due to high expected recurrence

Exclusion criteria

allergic to alpha-lipoic acid
severe heart failure, lung disease, or end-stage renal disease
liver function abnormalities (x2.5 above normal limits)
neuropsychologically unstable patients
previous history of drug medication such as oral steroid, digoxin, theophylline, carbamazepine, valproic acid, phenobarbital, methotrexate, cyclosporin, tacrolimus within 3 months before this recruitment.
who is already taking alpha-lipoic acid for other purpose.